Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04348292 · ClinicalTrials.gov registry record · Phase 1
Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04348292 is a Phase 1 study that was terminated before completion, run by Emory University. The registered enrollment target is 3 participants.
The verdict
NCT04348292, a Phase 1 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This trial studies the side effects of sirolimus and durvalumab and to see how well they work in treating patients with stage I-IIIA non-small cell lung cancer. Sirolimus is an oral medication that blocks the mTOR cellular pathway which may help the immune system work better. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sirolimus before durvalumab may help the immune system get rid of cancer.
Interventions
- DRUG Sirolimus
- DRUG Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-01-22 |
| Est. Completion | 2022-11-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04348292
The ClinicalTrials.gov registry entry for NCT04348292 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.
NCT04348292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04348292 about?
NCT04348292 is a clinical study titled "Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer". This trial studies the side effects of sirolimus and durvalumab and to see how well they work in treating patients with stage I-IIIA non-small cell lung cancer. Sirolimus is an oral medication that blocks the mTOR cellular pathway which may help the immune system work better. Immunotherapy with mono...
What is the current status of trial NCT04348292?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-01-22. Estimated completion is 2022-11-04.
What interventions are being tested in trial NCT04348292?
The interventions under investigation include: Sirolimus (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT04348292?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.